Seasoned investor with 20 years of experience and a strong track record strengthens VC’s leadership in early-stage life science investments PARIS, France – September 10, 2024 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of Karl Naegler as Partner. This strategic hire also […]
The first panel of the day, chaired by Mary Clark, our co-founder and CEO, saw a group of Europe’s leading investors – Hakan Goker, M Ventures; Maina Bhaman, Sofinnova Partners; Christian Elling, Lundbeckfonden; and Roel Bulthuis, Syncona – share sage advice for companies looking to raise funds, providing insights on the most important factors shaping […]
6TH OCTOBER 2022 | LONDON
In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023. According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery. Check out the Evaluate team’s thoughts on the […]
We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]
